Risk Factors for Targeted Fungal and Mycobacterial Infections in XXXX Taking @entity5 Necrosis Factor Inhibitors.

@entity1 @entity10592 @entity39 @entity5 @entity229 @entity281 @entity364 @entity3219 @entity17101 @entity6656 @entity378
OBJECTIVE: To identify predictors of the receipt of medical care, including the receipt of pre-drug screening, for diagnostically targeted fungal or @entity281 among @entity1 prescribed a @entity5 @entity39 factor inhibitor (TNFi). METHODS: We conducted a case-control study using deidentified @entity1 health claims information from a data set representing a commercially insured US population of 15 million @entity1 annually from January 1, 2007 to December 31, 2009. Descriptive statistics as well as a 2-sample t-test, chi-square test of association, Fisher's exact test, and multivariate logistic regression were used for data analysis. RESULTS: A total of 30,772 @entity1 received a TNFi during the study period. Of these, 158 @entity1 (0.51%) developed @entity364 (cases). The median number of @entity281 per case was 1.0 (interquartile range 1.0-2.0). @entity378 was diagnosed in 61% of cases, followed by @entity3219 in 60%, nontuberculous @entity281 in 11%, @entity6656 in 10%, unspecified @entity364 in 8%, @entity17101 in 4%, @entity281 in 3%, and @entity10592 in 2%. Compared to controls (n   = 474), a higher proportion of cases were prescribed @entity229 (55% versus 37%; P < 0.001). @entity1 who were prescribed @entity229 during the study period were twice as likely as those not taking @entity229 to seek medical care attributable to a targeted fungal or @entity281 (odds ratio 2.03; P < 0.001). CONCLUSION: Development of a targeted fungal or @entity281 among @entity1 taking a TNFi is rare. Concomitant use of @entity229 predicted development of such @entity281 .
